Abstract:Cancer immunotherapy has flourished over the last 10–15 years, transforming the practice of oncology and providing long-term clinical benefit to some patients. During this time, three distinct classes of immune checkpoint inhibitors, chimeric antigen receptor-T cell therapies specific for two targets, and two distinct classes of bispecific T cell engagers, a vaccine, and an oncolytic virus have joined cytokines as a standard of cancer care. At the same time, scientific progress has delivered vast amounts of new knowledge. For example, advances in technologies such as single-cell sequencing and spatial transcriptomics have provided deep insights into the immunobiology of the tumor microenvironment. With this rapid clinical and scientific progress, the field of cancer immunotherapy is currently at a critical inflection point, with potential for exponential growth over the next decade. Recognizing this, the Society for Immunotherapy of Cancer convened a diverse group of experts in cancer immunotherapy representing academia, the pharmaceutical and biotechnology industries, patient advocacy, and the regulatory community to identify current opportunities and challenges with the goal of prioritizing areas with the highest potential for clinical impact. The consensus group identified seven high-priority areas of current opportunity for the field: mechanisms of antitumor activity and toxicity; mechanisms of drug resistance; biomarkers and biospecimens; unique aspects of novel therapeutics; host and environmental interactions; premalignant immunity, immune interception, and immunoprevention; and clinical trial design, endpoints, and conduct. Additionally, potential roadblocks to progress were discussed, and several topics were identified as cross-cutting tools for optimization, each with potential to impact multiple scientific priority areas. These cross-cutting tools include preclinical models, data curation and sharing, biopsies and biospecimens, diversification of funding sources, definitions and standards, and patient engagement. Finally, three key guiding principles were identified that will both optimize and maximize progress in the field. These include engaging the patient community; cultivating diversity, equity, inclusion, and accessibility; and leveraging the power of artificial intelligence to accelerate progress. Here, we present the outcomes of these discussions as a strategic vision to galvanize the field for the next decade of exponential progress in cancer immunotherapy.

Ten challenges and opportunities in computational immuno-oncology

Historical perspective and future directions: computational science in immuno-oncology

Computational immunogenomic approaches to predict response to cancer immunotherapies

Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision

Navigating the Immune Maze: Pioneering Strategies for Un-shackling Cancer Immunotherapy Resistance

Facts and hopes in using omics to advance combined immunotherapy strategies

Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy

Computational Quantification of Cancer Immunoediting

Addressing current challenges in cancer immunotherapy with mathematical and computational modeling

1O Uncovering New Immunotherapy Targets with Machine Learning and Ex Vivo Validation

Computational methods and biomarker discovery strategies for spatial proteomics: a review in immuno-oncology

Beyond immune checkpoint blockade: emerging immunological strategies

Technological Advances in Cancer Immunity: from Immunogenomics to Single-Cell Analysis and Artificial Intelligence

Bioinformatics for cancer immunotherapy target discovery

Computational Advances in Cancer Informatics (A)

Emerging immunological strategies: recent advances and future directions

Spatial omics techniques and data analysis for cancer immunotherapy applications

Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank

Breakthroughs in AI and Multi-Omics for Cancer Drug Discovery: A Review

Proceedings of the 2016 China Cancer Immunotherapy Workshop

A brand new era of cancer immunotherapy: breakthroughs and challenges